Seer (SEER)
(Delayed Data from NSDQ)
$1.61 USD
+0.02 (1.26%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $1.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.61 USD
+0.02 (1.26%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $1.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth C Momentum D VGM
Zacks News
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seer (SEER) delivered earnings and revenue surprises of 2.78% and 7.61%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 400% and 15.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seer (SEER) delivered earnings and revenue surprises of -3.23% and 13.51%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 18.33% and 0.14%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 20% and 4.79%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Seer, Inc. (SEER) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Seer, Inc. (SEER), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 13.16% and 5.37%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 2.63% and 25.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of -2.70% and 1.33%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
NeoGenomics (NEO) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
NeoGenomics (NEO) delivered earnings and revenue surprises of 35.71% and 8.64%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
2seventy bio, Inc. (TSVT) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
2seventy bio, Inc. (TSVT) delivered earnings and revenue surprises of 9.24% and 115.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Alkermes (ALKS) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 133.33% and 1.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Intercept (ICPT) Moves 15.0% Higher: Will This Strength Last?
by Zacks Equity Research
Intercept (ICPT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Seer, Inc. (SEER) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 14.29% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Seer (SEER) Ahead of Earnings?
by Zacks Equity Research
Seer (SEER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Cara Therapeutics (CARA) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cara (CARA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Down -26.63% in 4 Weeks, Here's Why You Should You Buy the Dip in Seer, Inc. (SEER)
by Zacks Equity Research
Seer, Inc. (SEER) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Seer, Inc. (SEER) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Seer, Inc. (SEER) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Seer, Inc. (SEER) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Seer, Inc. (SEER) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Seer, Inc. (SEER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 0% and 6.60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Prothena (PRTA) delivered earnings and revenue surprises of -212.90% and 94.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 5.13% and 17.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Seer, Inc. (SEER) Stock Jumps 12.9%: Will It Continue to Soar?
by Zacks Equity Research
Seer, Inc. (SEER) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Seer, Inc. (SEER) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Seer, Inc. (SEER) delivered earnings and revenue surprises of 7.32% and 18.71%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?